Prevention of Acute Kidney Injury Through Biomarker-guided Nephrological Intervention

Robert Bosch Medical Center

Status: Completed

Conditions: Acute Kidney Injury

Treatments: Other: Early nephrologist consultation

Study type: Interventional

Funder types: Other

Identifiers

NCT02730637

RBK-348

Details and patient eligibility

About

This study examines the clinical relevance of early biomarkers to detect and prevent acute kidney injury. High-risk patients for developing acute kidney injury will be screened at initial presentation (emergency department and intensive care unit) for TIMP2xIGFBP7. In case of elevated readings patients will be randomized in two arms: The control group will be treated with standard care, the intervention group will receive an early nephrologic consultation.

Full description

This study examines the impact of an early biomarker-guided intervention on the development of acute kidney injury (AKI). New biomarkers indicate kidney damage in an early stage before developing acute kidney injury according to AKI Kidney Disease Improving Global Outcomes (KDIGO) Definition is detectable. The investigators want to test if it's possible to prevent AKI based on elevated urinary biomarkers. Eligible patients will be randomly assigned to two groups, a control and an intervention Group by an early nephrologic consultation. The interventional group will receive an early preventive nephrologist consultation additionally to standard care.

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• no acute kidney injury stage II-III (according to AKI KDIGO definition)
• urinary biomarker levels above cut-off
• inpatient treatment
• age ≥18 years
• informed consent or presumed will

Exclusion criteria

• existing acute kidney injury stage II-III (according to AKI KDIGO definition)
• age < 18 years
• end stage renal disease (ESRD), existing renal replacement therapy
• pregnancy
• withdrawal of consent
• missing presumed will

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups

Standard care

No Intervention group

Description:

Patients with elevated biomarkers receive a standard treatment.

Interventional care

Active Comparator group

Description:

Patients in the interventional population receive an early nephrologist consultation which deliberates with attending doctor on preventing measures according to AKI-KDIGO recommendations.

Treatment:

Other: Early nephrologist consultation